Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Lonza Group    LONN   CH0013841017

LONZA GROUP (LONN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
04/18/2018 04/19/2018 04/20/2018 04/23/2018 04/24/2018 Date
241(c) 245.3(c) 245(c) 244.7(c) 244.3 Last
317 459 411 059 402 003 280 833 325 909 Volume
-0.21% +1.78% -0.12% -0.12% -0.16% Change
More quotes
Financials (CHF)
Sales 2018 5 973 M
EBIT 2018 1 106 M
Net income 2018 731 M
Debt 2018 3 651 M
Yield 2018 1,28%
Sales 2019 6 329 M
EBIT 2019 1 243 M
Net income 2019 860 M
Debt 2019 3 133 M
Yield 2019 1,47%
P/E ratio 2018 26,04
P/E ratio 2019 21,84
EV / Sales2018 3,68x
EV / Sales2019 3,39x
Capitalization 18 303 M
More Financials
Company
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products.It operates through the Pharma&Biotech and Specialty Ingredients segemnts.The Pharma&Biotech segment deals with the supply of pharmaceutical ingredients and biopharmaceuticals as well as research and... 
Sector
Biotechnology & Medical Research
Calendar
05/04 | 10:00amShareholder meeting
More about the company
Surperformance© ratings of Lonza Group
Trading Rating : Investor Rating :
More Ratings
Latest news on LONZA GROUP
04/23GLOBAL FIRE SAFE PLYWOOD MARKET 2018 : 9strategy.biz added a depth and professio..
AQ
04/23LONZA : Publishes Additional Details About Long-Term Incentive Plan (LTIP) Targe..
AQ
04/20LONZA : Stefan Verseck Joins Lonza as Technology Scout and Biotechnology Expert
AQ
04/20LONZA : Jennifer Clancy Joins Lonza as Head of Global Marketing
AQ
04/20LONZA : Showcases BioActives to Shield Skin from Urban Lifestyle and Environment..
AQ
04/19LONZA : New Pulsar® Infinity Feeder Offers Superior Protection with Low Maintena..
PU
04/19LONZA : New CCH® Endurance Feeder Offers Superior Protection with Low Maintenanc..
PU
04/18LONZA : Consumer Health and Nutrition to Present Cutting-Edge Delivery Solutions..
PU
04/17Lonza Publishes Additional Details About Long-Term Incentive Plan (LTIP) Targ..
TE
04/17LONZA : Publishes Additional Details About Long-Term Incentive Plan (LTIP) Targe..
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Biotechnology & Medical Research - NEC
4-Traders Strategies on LONZA GROUP 
LONZA GROUP - 04/20
Technically solid
BUY
LONZA GROUP - 01/24
The stock forcefully approaches new pivot levels
BUY
More Strategies
Latest Tweets
04/23Synpromics Awarded Innovate UK Grant to Evaluate Its Inducible Promoter Platf.. 
04/23Synpromics Awarded Innovate UK Grant to Evaluate Its Inducible Promoter Platf..
1
04/17$LONN Group AG Despite More Optimistic Outlook for Lonza After 4Q, Shares Re.. 
04/12New Lonza facility - said to be the world's biggest plant dedicated cell-and-.. 
04/12Lonza opens largest gene therapy plant in the world and hires 200 scientists:.. 
More tweets
Qtime:45
News from SeekingAlpha
01/31Lonza Group AG ADR 2017 Q4 - Results - Earnings Call Slides 
01/31Lonza Group AG reports FY results 
2017Oppenheimer International Growth Fund Inst (OIGYX) November Summary 
2017Oppenheimer International Growth Fund Inst (OIGYX) October Summary 
2017Oppenheimer International Growth Fund Inst (OIGYX) September Summary 
Chart LONZA GROUP
Duration : Period :
Lonza Group Technical Analysis Chart | LONN | CH0013841017 | 4-Traders
Technical analysis trends LONZA GROUP
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 284  CHF
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Richard Ridinger Chief Executive Officer
Rolf Soiron Chairman
Rodolfo Savitzky Chief Financial Officer
Patrick Aebischer Vice Chairman
Jean-Daniel Gerber Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP-6.95%18 717
CELLTRION, INC.--.--%31 467
IQVIA HOLDINGS INC-0.64%20 258
INCYTE CORPORATION-27.75%14 493
NEKTAR THERAPEUTICS44.36%13 873
ALNYLAM PHARMACEUTICALS, INC.-23.27%9 765